No abstract

Background:Predictive models to identify low-risk febrile neutropenia (FN) have been developed with heterogeneous samples, which included stable and unstable patients, solid tumours, acute leukaemia and bone marrow transplantation. These models fail to recognise 5–15% of cases with unexpected complications, and literature specifically addressing apparently stable patients (ASPs) is scarce.Methods:We reviewed 861 episodes of FN in outpatients with solid tumours, including 692 (80%) episodes with apparent clinical stability. We aimed to investigate the prognosis of this latter group and explore the possibility of stratifying it according to the presenting features. A case–control study was performed and the MASCC index was evaluated.Results:The rates of complications and bacteraemia in ASPs were 7.3% and 6.2%, respectively. The MASCC index yielded a low sensitivity to detect complications (36%). Prognostic factors were identified: ECOG performance status ⩾2, chronic bronchitis, chronic heart failure, stomatitis NCI grade ⩾2, monocytes <200 mm−3 and stress hyperglycaemia.Conclusion:A very simple assessment is useful to classify the patients with FN according to the risk of complications. A few additional variables may predict the clinical course of the patients. We additionally show that the MASCC index applied to this specific group has a low sensitivity to predict complications.

Purpose -As with the ISO 9000 standard, some doubts arise from the scientific literature about the impact of the EFQM model in companies' success. This paper aims to present an analysis of the relationships in the 2003 version of the EFQM model using data from the actual self-evaluations of 68 organizations. It also analyzes if there are possible differences in the EFQM implementation between public and private organizations. Design/methodology/approach -The Partial Least Squares (PLS) method is used to test hypotheses. Findings -Results show that the model does not behave in the way that the designers of the EFQM expected. Two of the results variables are not sufficiently correlated with the others to be part of the complete model. When the model is tested without these two variables, the connection between enablers fails, since policy and strategy, people, and partnership and resources do not have statistically significant effects on the process. There is a slightly higher achievement in the group of manufacturing/private companies compared with the group of public/educational institutions. Research limitations/implications -This paper is an exploratory study. A deeper analysis of the agency criteria might produce improved results. It would also be possible to examine sub-criterion levels. Each enabler in the model is composed of different sub-criteria and the relationships among them have not been explored in the literature. The question that needs to be addressed is whether the inclusion of enablers in the EFQM Excellence Model can be justified on empirical grounds. Originality/value -Previous research has been conducted using secondary data. The study has been made using the real self-evaluations of organizations, evaluations that have been validated by official staff of the EFQM organization. In addition, whereas much of the previous research analysed the 1999 version of the model, this paper focuses on the latest version of 2003.

The aim of the study presented here was to assess the efficacy and tolerability of linezolid in the treatment of orthopedic implant infections (OII). Eighty-five patients with an OII treated with linezolid were prospectively followed up for a minimum of 12 months from the end of antibiotic therapy. Outcome was evaluated in relation to the duration and type of symptoms (acute or chronic) and the retention or removal of the implant. For acute and chronic infections, the respective success rates were 100 and 92.3% when the implant was removed and 72.2 and 42.8% when it was not. The median length of linezolid treatment in acute and chronic infections was 47 and 60 days, respectively. Thrombocytopenia was observed in four (4.7%) patients and anemia in five (5.8%). The results suggest oral linezolid is an effective and well-tolerated alternative for treating OII.

Access to this document was granted through an Emerald subscription provided by emerald-srm: 463575 [] For AuthorsIf you would like to write for this, or any other Emerald publication, then please use our Emerald for Authors service information about how to choose which publication to write for and submission guidelines are available for all. Please visit www.emeraldinsight.com/authors for more information. About Emerald www.emeraldinsight.comEmerald is a global publisher linking research and practice to the benefit of society. The company manages a portfolio of more than 290 journals and over 2,350 books and book series volumes, as well as providing an extensive range of online products and additional customer resources and services.Emerald is both COUNTER 4 and TRANSFER compliant. The organization is a partner of the Committee on Publication Ethics (COPE) and also works with Portico and the LOCKSS initiative for digital archive preservation.Micaela Martínez-Costa (mili@um.es) is associate professor of operations management at the University of Murcia (Spain). Her research mainly focuses on quality management and its relationship with company performance.